Alnylam Pharmaceuticals, Inc.
ALNY
$438.93
$3.830.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -337.46% | 18.78% | 36.82% | 34.83% | 93.14% |
| Total Depreciation and Amortization | 5.43% | -13.48% | -35.23% | -62.68% | -65.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.20% | 9.63% | -1.84% | -2.02% | -8.78% |
| Change in Net Operating Assets | -209.53% | -955.41% | -432.33% | -546.76% | -122.33% |
| Cash from Operations | -104.17% | -123.85% | -107.98% | 2,766.45% | 178.75% |
| Capital Expenditure | 31.55% | 50.61% | 44.90% | 40.92% | 21.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 67.97% | 135.59% | 69.88% | -58.08% | -247.58% |
| Cash from Investing | 61.15% | 119.69% | 65.26% | -29.28% | -420.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 28.26% | 149.30% | 105.44% | 71.72% | -28.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -334.90% | -172.20% | -135.64% | -79.76% | -20.98% |
| Cash from Financing | -0.51% | 99.99% | 70.89% | 54.01% | -49.42% |
| Foreign Exchange rate Adjustments | 551.88% | 252.99% | -338.44% | 547.84% | -253.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -53.52% | 3,174.45% | 386.50% | 267.47% | 278.42% |